Side Effects of Sermorelin Therapy
Many patients on sermorelin therapy have developed anti-GHRH antibodies at least once during treatment. However, the significance and long-term effects of these antibodies is unclear, and a positive test is often only temporary. The presence of these antibodies does not appear to lead to specific adverse effects or modulate growth.
No generalized allergic reactions to Side effects of SERMORELIN have been reported. The most common treatment-related adverse event (occurring in approximately one in six patients) is a local injection site reaction, which usually presents as redness, pain, or swelling. The injection site reaction can sometimes be serious; for example, of the 350 patients treated with sermorelin in a clinical trial, three discontinued therapies because of these injection site reactions. Other treatment-related adverse events were rare, with an incidence of <1%, and included hives, headache, sleepiness, flushing, dysphagia, dizziness, and hyperactivity.
There is little evidence to suggest that sermorelin is associated with any drug abuse or dependence and there have been no reports of this from clinical trials.